Piramal Imaging announced that results from four studies evaluating the Company’s PET amyloid imaging agent (florbetaben F18*) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver fromJune 8-12.
Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and highlights on florbetaben PET imaging in clinical trials as part of SNMMI’s Emerging Technologies Session on Neurodegenerative Imaging on Monday, June 10 at 12:00 p.m. in the West Building, room 306. Dr. Stephens’ presentation will highlightthe clinical experience with florbetaben which is based on more than 900 applications at imaging centers across the U.S., Europe, Japan and Australia. The florbetaben development program comprises six phase 1 studies, two global, multicenter phase 2 studies, an MCI study with two year follow-up, and a global, multicenter histopathology phase 3 study. “This year’s annual meeting marks an important time as we look to commercialize florbetaben,” said Dr. Stephens. “Our clinical presentations at SNMMI further highlight Piramal Imaging’s commitment to advance the early detection of Alzheimer’s disease as well as our research to develop investigational radiopharmaceuticals to address major clinical needs in oncology, specifically prostate cancer.” Florbetabenis currently being reviewed by the Food and Drug Administration(FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.Presentations highlighting Florbetaben and the Company’s pipeline compounds include:
Close to clinical routine phase 2 trial on florbetaben PET imaging of â-amyloid (Aâ) in lzheimer's disease (AD)[Abstract #299]
Scientific Paper Session (Oral) Neuroscience: Tau and Amyloid Imaging Tuesday, June 11, 8:00 - 8:12 a.m., West Building, Room 215-216 Reliability, reproducibility and efficacy of the 18F florbetaben â-amyloid PET scan visual assessment method as trained via a computer-based instructional tool [Abstract #300]
Scientific Paper Session (Oral) Neuroscience: Tau and Amyloid Imaging Tuesday, June 11, 8:12 – 8:24 a.m., West Building, Room 215-216 Age-dependent 18-F florbetaben brain PET uptake in adults with Down's syndrome [Abstract #468]
Scientific Paper Session (Oral) Prediction of Cognitive Dysfunction and Multimodal Imaging
Tuesday, June 11, 2:57 – 3:09 p.m., West Building, Room 215-216 Effects of a partial volume correction on [18F]florbetaben PET for the assessment of longitudinal â-amyloid load in APP-Swe mice [Abstract #1754]
Start investing in Equities, Derivatives, Mutual Funds and Currency
Temporary Password will be sent to your Mobile No. / Email Address to reset your password.
Make smart financial decisions
Trusted by more than 25 Lakhs Indians
Research and Stocks
Strategy and Tools
Terms & Conditions
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in National Do Not Call Registry as laid down by Telecom Regulatory Authority of India will not be applicable for such information/ communication.